Antidepressants differ in side-effects such as weight gain, UK research finds

A major review by King's College London and Oxford University found significant variations in physical side effects among 30 different antidepressants, with some causing notable weight changes (e.g., 2.5kg loss on agomelatine vs. 2kg gain on maprotiline) and impacts on heart rate and blood pressure within two months. The study, involving over 58,000 people, highlighted that commonly prescribed SSRIs generally exhibit fewer physical side effects, prompting researchers to call for updated treatment guidelines to support personalized patient care and informed decision-making.

Analysis

A major review by King's College London and the University of Oxford, encompassing 151 clinical studies and over 58,000 patients, revealed significant variations in physical side effects across 30 different antidepressant medications. This research highlighted notable changes in body weight, heart rate, and blood pressure, often within the first two months of treatment.

For instance, the study identified a difference of up to 4kg in average weight change between certain drugs, with agomelatine associated with approximately 2.5kg of weight loss and maprotiline with about 2kg of weight gain. Similarly, heart rate differences of 21 beats per minute and blood pressure variations of 11 mmHg were observed between specific medications.

While commonly prescribed SSRIs generally exhibited fewer physical side effects, researchers are advocating for updated antidepressant treatment guidelines to promote personalized care and informed decision-making. This broad industry development, classified under "Healthcare & Biotech" and "Regulation & Legislation," carries a neutral immediate market impact.

The findings suggest a potential shift in prescribing patterns towards drugs with more favorable side effect profiles or increased monitoring for others. This could influence future drug development and market positioning for pharmaceutical companies, particularly those with significant antidepressant portfolios, as clinicians and patients prioritize individualized treatment outcomes.

Key Decisions for Investors

• Investors should closely monitor any forthcoming updates to antidepressant treatment guidelines, as these could influence prescribing patterns and market share for specific drug classes or individual medications.
• Evaluate pharmaceutical companies' antidepressant portfolios for exposure to drugs with more pronounced physical side effects versus those with fewer, particularly SSRIs, as this research may drive long-term shifts in demand.
• Focus on pharmaceutical companies investing in novel antidepressant therapies with improved side effect profiles, as personalized medicine and patient-centric outcomes gain increasing importance in the healthcare sector.